Literature DB >> 18415047

Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.

Ronak Vakil1, Kayla Knilans, David Andes, Glen S Kwon.   

Abstract

PURPOSE: Rapamycin and 5-fluorocytosine (5-FC) are antifungal agents with unique mechanisms of activity, with potential for cooperative interaction with AmB. Combination antifungal therapy involving conventional AmB has been restricted by poor physical stability and compatibility with antifungal drugs and vehicles.
METHODS: AmB and rapamycin were encapsulated in 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy poly(ethylene glycol) (PEG-DSPE) micelles using a solvent evaporation method. The physical stability of micelle encapsulated AmB and rapamycin with 5-FC and saline was evaluated using dynamic light scattering (DLS). In vitro susceptibility of Candida albicans isolates to 5-FC and PEG-DSPE micelle solubilized AmB and rapamycin has been evaluated. Interactive effects have been quantified using a checkerboard layout.
RESULTS: In contrast with conventional AmB, PEG-DSPE micelles encapsulating AmB and rapamycin are compatible with saline and 5-FC over 12 h. The solubilized drugs retain high level of potency in vitro. The combination of solubilized AmB and rapamycin was indifferent, as fractional inhibitory concentration (FIC) index and combination index (CI) values were approximately 1. Combinations of solubilized AmB or rapamycin with 5-FC, and the three-drug combination were moderately synergistic since the FIC index and CI values were consistent less than 1.
CONCLUSIONS: These results indicate that AmB solubilized in PEG-DSPE micelles is compatible with solubilized rapamycin and 5-FC. The indifferent or moderately synergistic activity of combinations is encouraging and warrants further investigation in appropriate rodent models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18415047     DOI: 10.1007/s11095-008-9588-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  36 in total

1.  In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Authors:  S Shadomy; G Wagner; E Espinel-Ingroff; B A Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

2.  Solubilization of rapamycin.

Authors:  P Simamora; J M Alvarez; S H Yalkowsky
Journal:  Int J Pharm       Date:  2001-02-01       Impact factor: 5.875

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Compatibility of amphotericin B with certain large-volume parenterals.

Authors:  R W Jurgens; P P DeLuca; D Papadimitriou
Journal:  Am J Hosp Pharm       Date:  1981-03

Review 5.  Current treatment strategies for disseminated candidiasis.

Authors:  Brad J Spellberg; Scott G Filler; John E Edwards
Journal:  Clin Infect Dis       Date:  2005-12-02       Impact factor: 9.079

6.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

7.  Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

Authors:  J Arroyo; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

8.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Authors:  William J Steinbach; Wiley A Schell; Jill R Blankenship; Chiatogu Onyewu; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.

Authors:  M S Espuelas; P Legrand; M A Campanero; M Appel; M Chéron; C Gamazo; G Barratt; J M Irache
Journal:  J Antimicrob Chemother       Date:  2003-07-29       Impact factor: 5.790

10.  Interactive effects of antifungal and antineoplastic agents on yeasts commonly prevalent in cancer patients.

Authors:  M A Ghannoum; M S Motawy; M A Abu Hatab; K H Abu Elteen; R S Criddle
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

View more
  10 in total

1.  Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.

Authors:  Jun-Pil Jee; Aaron McCoy; Sandro Mecozzi
Journal:  Pharm Res       Date:  2011-07-08       Impact factor: 4.200

Review 2.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

3.  Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.

Authors:  Robert J Bastidas; Cecelia A Shertz; Soo Chan Lee; Joseph Heitman; Maria E Cardenas
Journal:  Eukaryot Cell       Date:  2011-12-30

4.  Amphotericin B/sterol co-loaded PEG-phospholipid micelles: effects of sterols on aggregation state and hemolytic activity of amphotericin B.

Authors:  Thomas A Diezi; Glen Kwon
Journal:  Pharm Res       Date:  2011-12-01       Impact factor: 4.200

Review 5.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 6.  Signaling cascades as drug targets in model and pathogenic fungi.

Authors:  Robert J Bastidas; Jennifer L Reedy; Helena Morales-Johansson; Joseph Heitman; Maria E Cardenas
Journal:  Curr Opin Investig Drugs       Date:  2008-08

7.  Spray-dried microparticles containing polymeric micelles encapsulating hematoporphyrin.

Authors:  Yu-Tsai Yang; Chin-Tin Chen; Jen-Chang Yang; Tsuimin Tsai
Journal:  AAPS J       Date:  2010-01-26       Impact factor: 4.009

8.  A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations.

Authors:  Rasmus Bojsen; Birgitte Regenberg; David Gresham; Anders Folkesson
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

9.  Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat.

Authors:  Connie M Remsberg; Yunqi Zhao; Jody K Takemoto; Rebecca M Bertram; Neal M Davies; Marcus Laird Forrest
Journal:  Pharmaceutics       Date:  2012-12-27       Impact factor: 6.321

Review 10.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.